A novel pan class-I glucose transporter inhibitor DRB18 exhibits synergistic effects in vitro and in vivo with paclitaxel against human non-small cell lung cancer

Cancer cells depend on glucose for biomass synthesis, cell proliferation, and drug resistance. They act like high-performance engines requiring a massive fuel supply to maintain rapid growth. This uptake is managed by specialized "doors" in the cell membrane known as glucose transporters (GLUTs). Because many cancers upregulate these transporters to feed their growth, blocking these doors has long been an attractive anticancer strategy.

However, targeting a single transporter often fails. Cancer cells are metabolically flexible. If you block one door, they simply use another. A new study from researchers at Ohio University suggests that the key to breaking this resistance is shutting down the entire class of "doors" simultaneously. The authors report that a second-generation inhibitor called DRB18 can effectively starve cancer cells. Crucially, it works in synergy (where the combined effect is greater than the sum of individual parts) with existing chemotherapy to produce much stronger results.

The redundancy of glucose transport

The current challenge in metabolic oncology is the redundancy of the GLUT protein family. Most cancer cells rely heavily on GLUT1. However, they often express multiple members of the Class I GLUT family (GLUT1–4) to ensure they can always access fuel. The authors note that previous attempts to target only GLUT1 failed. Specifically, knocking out the GLUT1 gene in NSCLC A549 cells did not reduce tumor growth in mice [38]. This happened because other GLUT proteins compensated for the loss.

This compensation creates a moving target for clinicians. If a drug only inhibits one isoform (a specific version of a protein), the tumor can adapt. This leads to the drug resistance that makes non-small cell lung cancer (NSCLC) so difficult to treat. The study identifies a specific clinical signature of this problem: the co-expression of GLUT1 and GLUT3. The researchers find that in lung adenocarcinoma (LUAD), patients with high levels of both proteins have significantly poorer survival rates than those with low levels of both .

This suggests these transporters work together to drive an aggressive, treatment-resistant metabolic phenotype.

Shutting the class-I gates

To address this redundancy, the authors utilized DRB18, a "pan-class I" inhibitor. Unlike earlier drugs that might target a single transporter, DRB18 is designed to bind to the outward-open conformation of GLUT1 through GLUT4. This approach is analogous to locking every exit in a building rather than just the front door. It prevents the cell from switching to an alternative route when its primary fuel source is cut off.

The mechanism of DRB18 involves disrupting the fundamental energetic state of the cell. The authors demonstrate that DRB18 reduces glucose uptake in several cancer lines, including A549, Panc1, and Hela cells [Figure 3F]. This reduction in fuel leads to a measurable drop in intracellular ATP (adenosine triphosphate)—the universal energy currency of the cell. Interestingly, the authors report that the potency of DRB18 is tied to the environment. Its effectiveness increases in the presence of higher extracellular glucose and ATP levels .

This suggests the drug works by creating a severe metabolic crisis that the cell cannot resolve through alternative nutrient scavenging.

Superior stability and synergistic killing

When evaluating new drug candidates, stability is as critical as raw potency. The researchers compared DRB18 to WZB117, a first-generation GLUT inhibitor. They found that WZB117 lost its anticancer activity after just 48 hours of incubation in serum [Figure 3B-C]. In contrast, DRB18 maintained its potency for at least 72 hours [Figure 3B-C]. Furthermore, the authors report that DRB18 showed higher inhibitory activity across a panel of nine major cancer types compared to WZB117 [Figure 3D].

The most striking evidence comes from combining DRB18 with paclitaxel, a standard chemotherapy for NSCLC. In vitro, the combination achieved a high synergy score of 17.56 [Figure 6A-B]. This was not a marginal improvement. The dual treatment drastically reduced cell proliferation compared to either drug alone. Moving into animal models, the results were even more pronounced. In mice with A549 tumors, the combination of DRB18 and paclitaxel reduced tumor volume by approximately 79%. It also reduced tumor weight by 87% compared to untreated controls [Figure 7A-C]. Crucially, the authors report that this massive reduction in tumor growth occurred without significant side effects. There were no significant differences in body weight or food consumption in the treated mice.

Limitations in dosage and scope

While the results are compelling, the study leaves several technical questions open. First, the researchers do not report the exact dosages used for all in vitro synergy experiments. They provide specific concentrations only for select combinations. For a researcher looking to model these interactions, this lack of granular dosing data makes it difficult to replicate the exact synergy profiles.

Second, the study focuses heavily on NSCLC and a handful of other cancer lines. The full breadth of DRB18's efficacy across all human malignancies remains unexplored. Finally, while the in vivo mouse models showed no immediate weight loss or food intake changes, the study does not address long-term systemic toxicity. It also does not explore how the drug might interact with the complex metabolic demands of healthy organs over an extended period.

The verdict: A promising metabolic wedge

If you are looking for a way to break the metabolic plasticity of lung cancer, this paper provides a strong signal. The move from single-target inhibition to pan-class I inhibition solves the fundamental problem of compensatory redundancy. By pairing DRB18 with paclitaxel, the researchers have demonstrated a way to hit the cancer cell with a "one-two punch." They disrupt its ability to fuel itself while simultaneously attacking its structural integrity.

Is it ready for the clinic? Not yet. The transition from xenograft mouse models to human patients requires rigorous safety profiling and large-scale clinical trials. However, the biological rationale is sound. The synergy observed in vivo is remarkable. If DRB18 can maintain this level of efficacy and safety in humans, it could transform the treatment of advanced NSCLC into a targeted metabolic strike.

Figures from the paper